HONG KONG – Kobiolabs Inc., a microbiome-based venture from Seoul, South Korea, has secured a KRW26.6 billion (US$22.2 million) investment. Founded in 2014, the venture has achieved KRW193 billion of enterprise value.

HONG KONG – South Korean pharmaceutical company Chong Kun Dang Holdings recently invested KRW5 billion (US$4.1 million) in Biorchestra Co. Ltd., a Korean startup based in Daejeon that aims to develop Alzheimer’s dementia treatment based on microRNA.

Cyteir Therapeutics Inc., a Lexington, Mass.-based company exploiting synthetic lethality to fight cancer, is extending its series B financing with $40.2 million to support a recently launched phase I/II study of its lead candidate, CYT-0851, an oral small-molecule inhibitor of the protein RAD51. 

DUBLIN – Abalos Therapeutics GmbH raised €12 million (US$13.2 million) in series A funding to advance a distinctive approach to harnessing viruses for immuno-oncology applications.

Phathom Pharmaceuticals Inc., of Buffalo Grove, Ill., set terms for its proposed IPO, disclosing plans to offer 7.9 million common shares priced in a range of $18 to $20 for a raise of approximately $136.8 million at the midpoint. 

LONDON – Healx Ltd. has raised a $56 million series B after demonstrating its artificial intelligence-driven drug repurposing platform can systematically uncover treatments for rare diseases.

HONG KONG – South Korea's 3billion Inc., a rare genetic diseases diagnosis startup based in Seoul, has secured ?11.4 billion (US$9.6 million) in a series B investment. The company was founded in 2016 as a spinoff of Macrogen Inc., a Seoul-based genetic sequencing biotech, and raised ?3 billion in a series A funding last year.

HONG KONG – Kobiolabs Inc., a microbiome-based venture from Seoul, South Korea, has secured a ?26.6 billion (US$22.2 million) investment. Founded in 2014, the venture has achieved ?193 billion of enterprise value.

LONDON – Mogrify Ltd. raised $16 million in the first close of a series A that it expects to at least double before closing the round in the next 12 months.

Aytu BioScience Inc., of Englewood, Colo., said it entered into definitive agreements with institutional investors Altium Capital and Armistice Capital for the purchase and sale in a private placement of $10 million of series F convertible preferred stock and warrants to purchase common stock.